Literature DB >> 29302247

Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.

David M Albala1.   

Abstract

Entities:  

Year:  2017        PMID： 29302247      PMCID： PMC5737351          DOI： 10.3909/riu193PracticeProfile

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  7 in total

Review 1.  Sequencing of agents in castration-resistant prostate cancer.

Authors:  David Lorente; Joaquin Mateo; Raquel Perez-Lopez; Johann S de Bono; Gerhardt Attard
Journal:  Lancet Oncol       Date:  2015-05-27       Impact factor: 41.316

2.  The changing landscape in the treatment of metastatic castration-resistant prostate cancer.

Authors:  Joelle El-Amm; Jeanny B Aragon-Ching
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

3.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

4.  Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.

Authors:  Yohann Loriot; Kurt Miller; Cora N Sternberg; Karim Fizazi; Johann S De Bono; Simon Chowdhury; Celestia S Higano; Sarah Noonberg; Stefan Holmstrom; Harry Mansbach; Frank G Perabo; De Phung; Cristina Ivanescu; Konstantina Skaltsa; Tomasz M Beer; Bertrand Tombal
Journal:  Lancet Oncol       Date:  2015-04-14       Impact factor: 41.316

Review 5.  The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).

Authors:  E David Crawford; Daniel P Petrylak; Neal Shore; Fred Saad; Susan F Slovin; Nicholas J Vogelzang; Thomas E Keane; Phillip J Koo; Leonard G Gomella; Joe M O'Sullivan; Bertrand Tombal; Raoul S Concepcion; Paul Sieber; Nelson N Stone; Steven E Finkelstein; Evan Y Yu
Journal:  Urology       Date:  2017-03-14       Impact factor: 2.649

6.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

7.  Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Authors:  Andrew J Armstrong; Fred Saad; Carl Dmuchowski; Neal D Shore; Karim Fizazi; Mohammad Hirmand; David Forer; Howard I Scher; Johann De Bono
Journal:  Cancer       Date:  2017-02-07       Impact factor: 6.860
  7 in total
  4 in total

1.  Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression.

Authors:  Kathleen Ruchalski; Hyun J Kim; Michael Douek; Steven Raman; Maitraya Patel; Victor Sai; Antonio Gutierrez; Benjamin Levine; Cheryce Fischer; Martin Allen-Auerbach; Pawan Gupta; Heidi Coy; Bianca Villegas; Matthew Brown; Jonathan Goldin
Journal:  Cancer Imaging       Date:  2022-07-14       Impact factor: 5.605

2.  HGK promotes metastatic dissemination in prostate cancer.

Authors:  Sara Garcia-Garcia; Maria Rodrigo-Faus; Noelia Fonseca; Sara Manzano; Balázs Győrffy; Alberto Ocaña; Paloma Bragado; Almudena Porras; Alvaro Gutierrez-Uzquiza
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

3.  Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.

Authors:  Neal Shore; Celestia S Higano; Daniel J George; Cora N Sternberg; Fred Saad; Bertrand Tombal; Kurt Miller; Jan Kalinovsky; XiaoLong Jiao; Krishna Tangirala; Oliver Sartor
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-05-13       Impact factor: 5.455

Review 4.  Imaging of Oligometastatic Disease.

Authors:  Naik Vietti Violi; Rami Hajri; Laura Haefliger; Marie Nicod-Lalonde; Nicolas Villard; Clarisse Dromain
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.